[1]余莉萍,余淑菁,张萌,等.麻黄升麻达原汤治疗重症肺炎痰热壅肺证疗效及对患者血清IL-17、IL-12P70、CD64水平的影响[J].陕西中医,2026,(4):487-491.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.010]
　YU Liping,YU Shujing,ZHANG Meng,et al.Efficacy of Mahuang Shengma Dayuan decoction in treating severe pneumonia cases with syndrome of phlegm-heat obstructing the lung and its effect on serum levels of IL-17,IL-12P70,CD64[J].,2026,(4):487-491.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.010]
点击复制

麻黄升麻达原汤治疗重症肺炎痰热壅肺证疗效及对患者血清IL-17、IL-12P70、CD64水平的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年4期
页码:
487-491
栏目:
临床研究
出版日期:
2026-04-05

文章信息/Info

Title:
Efficacy of Mahuang Shengma Dayuan decoction in treating severe pneumonia cases with syndrome of phlegm-heat obstructing the lung and its effect on serum levels of IL-17,IL-12P70,CD64
作者:
余莉萍1; 余淑菁2; 张萌2; 周芳1; 张栋1; 喻灿1; 高宇1; 张军1; 李旭成1
（1.武汉市中医医院，湖北 武汉 430050；2.武汉市荣军优抚医院，湖北 武汉 430023）
Author(s):
YU Liping1; YU Shujing2; ZHANG Meng2; ZHOU Fang1; ZHANG Dong1; YU Can1; GAO Yu1; ZHANG Jun1; LI Xucheng1
（1.Wuhan Hospital of Traditional Chinese Medicine，Wuhan 430000，China；2.Wuhan Rongjun Special Care Hospital，Wuhan 430023，China）
关键词:
重症肺炎; 麻黄升麻达原汤; 白细胞介素-17; 白细胞介素-12P70; 簇分化抗原64
Keywords:
Severe pneumonia; Mahuang Shengma Dayuan decoction; Interleukin-17; Interleukin-12P70; Cluster differentiation antigen 64
分类号:
R 256.1
DOI:
DOI:10.3969/j.issn.1000-7369.2026.04.010
文献标志码:
A
摘要:
目的：探讨麻黄升麻达原汤治疗重症肺炎（SP）痰热壅肺证患者的疗效及对血清白细胞介素（IL）-17、IL-12P70、簇分化抗原64（CD64）水平的影响。方法：选取104例SP患者，根据随机数字表法分成联合组与对照组，每组52例。对照组患者采取常规治疗措施。联合组于对照组基础上予麻黄升麻达原汤治疗。两组均治疗14 d。比较两组SP患者APACHE Ⅱ评分、临床肺部感染评分（CPIS）、呼吸功能、痰热壅肺证症状评分、临床疗效以及血清白细胞介素（IL）-17、IL-12P70、簇分化抗原64（CD64）水平。结果：两组SP患者治疗后APACHE Ⅱ与CPIS评分均明显降低，且联合组患者降低更明显（均P＜0.05）；两组SP患者治疗后用力肺活量（FVC）明显增加，呼吸频率明显减少，且联合组患者以上指标改善更优（均P＜0.05）；两组SP患者治疗后痰热壅肺证症状评分明显降低，且联合组患者明显低于对照组（均P＜0.05）；两组SP患者治疗后血清IL-17、IL-12P70、CD64水平明显降低，且联合组患者明显低于对照组（均P＜0.05）；联合组SP患者总有效率96.15％明显高于对照组的78.85％（P＜0.05）。结论：麻黄升麻达原汤治疗SP痰热壅肺证疗效显著，能改善肺部感染，改善呼吸功能与中医证候，并且下调血清IL-17、IL-12P70、CD64水平。
Abstract:
Objective:To investigate the efficacy of Mahuang Shengma Dayuan decoction in treating severe pneumonia cases with syndrome of phlegm-heat obstructing the lung and its effect on serum levels of interleukin (IL)-17,IL-12P70,cluster differentiation antigen 64(CD64).Methods:A total of 104 cases of SP were divided into the combined group and the control group according to the random number table method with 52 cases in each group.The control group was treated with conventional measures based on the guidelines.The combined group was treated with Mahuang Shengma Dayuan decoction on the basis of the control group.Both groups were observed for 14 days.The APACHE Ⅱ score,clinical pulmonary infection score (CPIS),respiratory function,symptoms score of syndrome of phlegm-heat obstructing the lung,the clinical efficacy,and serum levels of IL-17,IL-12P70,and CD64 were compared between the two groups.Results:After treatment,the APACHE Ⅱ and CPIS scores of the SP cases in both groups were evidently reduced,and the reduction was more evident in the combined group (all P<0.05).After treatment,the forced vital capacity (FVC) of the SP cases in both groups was evidently increased and the respiratory rate was evidently decreased,and the improvement in the combined group was better (all P<0.05).After treatment,the symptoms score of phlegm-heat obstructing the lung of the SP cases in both groups was evidently reduced,and the score in the combined group was evidently lower than that in the control group (all P<0.05).After treatment,serum levels of IL-17,IL-12P70，and CD64 of the SP cases in both groups were evidently reduced,and the levels in the combined group were evident lower than those in the control group (all P<0.05).The total effective rate of the SP cases in the combined group was 96.15%,which was evidently higher than 78.85% in the control group (P<0.05).Conclusion:The therapeutic effect of Mahuang Shengma Dayuan decoction in treating severe pneumonia cases with syndrome of phlegm-heat obstructing the lung is remarkable,can promote the control of pulmonary infection,improve respiratory function and traditional Chinese medicine syndrome,and reduce serum levels of IL-17,IL-12P70 and CD64.

参考文献/References:

[1]罗成,宁博,张馨月,等.重症肺炎与信号通路的关系及中药调控进展[J].中国实验方剂学杂志,2025,31(8):294-302.
[2]谢云,高娇,任茂,等.千金苇茎汤合麻杏石甘汤加减联合胸腺法新治疗老年重症肺炎临床观察[J].河北中医,2023,45(8):1292-1296，1301.
[3]章怡祎,张伟珍,陈伟.重症肺炎患者中医证候特征与中医药治疗进展[J].世界科学技术-中医药现代化,2020,22(11):4033-4038.
[4]尤文,周丽雅.中医药治疗重症肺炎研究进展[J].陕西中医,2021,42(4):543-545.
[5]谢参业,朱达,石明洁,等.叶勇教授救治重症肺炎临床经验[J].中国中医急症,2024,33(3):526-528，536.
[6]杨径,孟新科,申群喜,等.APACHE Ⅲ、SAPS Ⅱ、MPM Ⅱ0与APACHE Ⅱ在急诊内科危重病人病情评估中的比较[J].中国急救医学,2002，22(2):19-21.
[7]中国医师协会急诊医师分会.中国急诊重症肺炎临床实践专家共识[J].中国急救医学,2016,36(2):97-107.
[8]中华中医药学会内科分会.社区获得性肺炎中医诊疗指南(2018修订版)[J].中医杂志,2019,60(4):350-360.
[9]郑宇,周光耀,陈朴,等.CPIS联合炎症介质水平在重症肺炎医院感染诊断中的价值与效能评价[J].中华医院感染学杂志,2019,29(19):2910-2915.
[10]国家食品药品监督管理局.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002:53-58.
[11]国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:286-287.
[12]张康,王海峰.清法在重症肺炎中的临床应用及作用机制[J].世界科学技术-中医药现代化,2023,25(8):2892-2899.
[13]施伟刚,马文通,夏茂红,等.老年重症肺炎患者重返ICU原因及预后的影响因素[J].河北医药,2024,46(8):1259-1263.
[14]张惠民，杜旭升，范亚莉，等.重症肺炎120例多重耐药菌感染情况及影响因素分析[J].陕西医学杂志，2022，51（7）：838-842.
[15]程方琳,杨硕,毛莉娜.千金汤加味治疗重症肺炎（痰热壅肺证）的临床观察[J].中国中医急症,2025,34(1):80-82.
[16]杨爱琴,韩晓燕,陈洁.宣壅清肺汤治疗老年重症肺炎临床观察[J].辽宁中医杂志,2024,51(6):74-77.
[17]郅红蕾,何莹莹,运苛政,等.基于肺肠同治理论探讨柴芩麻膏汤联合血必净注射液治疗重症肺炎患者的疗效观察[J].世界中西医结合杂志,2024,19(8):1587-1591.
[18]李虎年,张淑敏,杜芳,等.巨噬细胞移动抑制因子抑制剂ISO-1对重症肺炎大鼠炎症反应的影响[J].中国感染与化疗杂志,2023,23(3):334-340.
[19]杨艳,谢慧,张艳.重症肺炎患者血清NLRP3、YKL-40与炎症反应及预后的关系[J].中国卫生工程学,2021,20(3):503-506.
[20]李梦雪,刘琼,彭红星,等.红景天苷通过NF-κB/Bcl-2信号通路对重症肺炎大鼠肺血管内皮细胞凋亡及IL-23、Th17表达的影响[J].陕西中医,2024,45(6):745-750.
[21]于书娴,张威,刘汶睿,等.AECOPD合并肺炎患者外周血CD16+/56+NK细胞及IL-12p70、IL-10、IL-4、IFN-γ表达水平及意义分析[J].临床肺科杂志,2023,28(7):1024-1029.
[22]冯琳琳,姚鲁肃.重症肺炎患者SAA/CRP、活化蛋白C、CD64对病情转归的预测价值[J].检验医学与临床,2025,22(4):451-456.
[23]蔡剑英,陶学芳,王国文,等.重症肺炎患者血清IL-17及IL-12P70与CD64表达水平及其与预后的关系[J].中华医院感染学杂志,2024,34(16):2452-2456.
[24]苑萌,董慧文,刘佳丽,等.麻黄水提物减轻脂多糖诱导急性肺损伤的作用及机制研究[J].湖南中医药大学学报,2023,43(12):2185-2190.
[25]陈俊杰,杨道文.升麻素通过NF-κB通路对支气管上皮细胞过敏性炎症反应的抑制作用[J].中国免疫学杂志,2024,40(3):534-539.

相似文献/References:

[1]王 勤,张小方,张爱娥,等.医用磁贴联合通腑泻肺方治疗重症肺炎合并胃肠功能障碍临床研究*[J].陕西中医,2019,(2):264.
[2]黄丹虹,刘相圻.清气化痰汤联合纤维支气管镜肺泡灌洗吸痰治疗重症肺炎疗效及对患者血清T淋巴细胞亚群的影响[J].陕西中医,2019,(11):1541.
[3]王 敏,闫 蕾△.白虎承气汤治疗重症肺炎疗效及其作用机制研究[J].陕西中医,2019,(12):1693.
　WANG Min,YAN Lei..Study on the efficacy and mechanism of Baihu Chengqi decoction in the treatment of severe pneumonia[J].,2019,(4):1693.
[4]尤 文,周丽雅.中医药治疗重症肺炎研究进展[J].陕西中医,2021,(4):543.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.037]
　YOU Wen,ZHOU Liya.Treatment progress of Chinese medicine in severe pneumonia[J].,2021,(4):543.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.037]
[5]陈 韵,张星星,高志凌,等.清金化痰汤加减辅助抗生素治疗老年重症肺炎疗效及对患者炎症反应递质的影响[J].陕西中医,2022,(5):580.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.008]
　CHEN Yun,ZHANG Xingxing,GAO Zhiling,et al.Modified Qingjin Huatan decoction with antibiotics in the treatment of elderly severe pneumonia and its influence on inflammatory response transmitters[J].,2022,(4):580.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.008]
[6]史玉虎,王时光,施卫兵,等.健脾养肺汤联合西药抗感染治疗重症肺炎疗效及对患者血气指标、炎症因子的影响[J].陕西中医,2024,(2):213.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.014]
[7]李梦雪,刘 琼,彭红星,等.红景天苷通过 NF-κB/Bcl-2 信号通路对重症肺炎大鼠肺血管内皮细胞凋亡及IL-23、Th17表达的影响[J].陕西中医,2024,(6):745.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.005]
　LI Mengxue,LIU Qiong,PENG Hongxing,et al.Effects of salidroside on apoptosis of pulmonary vascular endothelial cells and IL-23,Th17 in rats with severe pneumonia through NF-κB/Bcl-2 signaling pathway[J].,2024,(4):745.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.005]

备注/Memo

备注/Memo:
湖北省中医药管理局中医药科研项目（ZY2025Q010）；武汉市中医药科研项目（WZ24B12）
更新日期/Last Update: 2026-04-05